Bird Flu confirmed in Gorakhpur: Chicken shops to be shut for 21 days
Gorakhpur: Bird flu has been confirmed in five localities of Gorakhpur, prompting authorities to shut all live bird markets across the city for the next 21 days. The decision follows laboratory confirmation of avian influenza strains H5N1 and H9N2 in poultry samples collected from the affected areas, Gorakhpur administration informed.
Samples were taken from birds in Jhungia Bazar, Aluminium Factory area, Taramandal, Bhagat Chauraha, and Shaheed Ashfaqullah Khan Zoological Park. These were sent to the National Institute of High Security Animal Diseases (NIHSAD), Bhopal, which confirmed the presence of the virus.
In response, the Chief Veterinary Officer (CVO) has activated district-level rapid response teams. A control room has also been set up at the Sadar Veterinary Hospital under the supervision of Manish Chandra.
Following the confirmation, additional municipal commissioner Nirankar Singh informed that as per Central Government guidelines, culling operations have begun within a 1-km radius of the infected zones. All live birds within this zone will be culled, and thorough disinfection drives are underway.
The CVO has appealed to the public not to believe in rumours and to cooperate with the administration. Meanwhile, poultry samples from various farms sent to IVRI Izzatnagar, Bareilly, tested negative for bird flu.
A total of 1,328 samples from Gorakhpur and 1,470 samples from the Gorakhpur-Basti division were tested during the surveillance exercise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
'Next Covid pandemic far from over': Delhi HC seeks details on sample collection
The Delhi High Court recently observed the "next Covid pandemic" was far from over as it asked for details on the Centre's preparedness for the collection of samples, centres and transport policy. Justice Girish Kathpalia said though it was sanguine that the steps and protocols would be in place, the same ought to be brought on record by the authorities concerned. "Considering that the next Covid pandemic is far from over and in fact, active, amongst the community, today, as per news reports, the vacuum, if any, of steps taken post the meeting of May 30, 2023, is a serious issue," the judge said. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Bank Owned Properties For Sale In Tula (Prices May Surprise You) Foreclosed Homes | Search ads Search Now Undo The court's May 28 order further said, "This assumes certain urgency, considering that there are wide reports of COVID-19 , being active in the community, as on date; it would, therefore, be expected from the respondent to crystallise an urgent set of measures, in order that these SoPs are in place and whatever decision was taken in the meeting, has reached its proper conclusion." The court was hearing a contempt plea filed by one Dr Rohit Jain alleging non-compliance by the authorities of an order passed by the division bench of the high court on January 27, 2023. Live Events The bench had disposed of Jain's plea on the issue while directing the Central government to treat it as a representation and decide it within 12 weeks through a reasoned order. Jain submitted despite the orders, no guidelines were framed by the Centre with respect to establishing minimum standards for sample collection, centres and transport. The court said the Centre's standing counsel Monika Arora should ensure that officers concerned were apprised of the court's directions and place a status report within the six weeks. The court then posted the hearing on July 18. It was informed that a meeting was held under the chairmanship of additional director general of health services on May 30, 2023 and the petitioner was also invited. In the meeting, a decision to constitute four sub-committees of experts of pathology, biochemistry, haematology and microbiology was arrived at. The committee members from the Centre-run hospitals were to define standards of procedure for sample collection, sample collection centres and the sample transport policy and submit a report. The guidelines were to include storage standards as well. The court, however, noted that there was no update provided by the authorities on the minutes of the meeting. Even though on first blush, the contempt petition may not subsist considering the decision that was taken to form the sub-committees, it said.
India Today
4 hours ago
- India Today
Covid far from over: Delhi court seeks report on sample testing as cases surge
The Delhi High Court has directed the Central government to submit a status report within six weeks on the policy for Covid-19 sample collection, transport and testing, stressing that the pandemic is "far from over". The court's order comes in light of recent news reports highlighting a rise in Covid-19 cases across the direction was issued on May 28 after the court noted that no update had been provided regarding the outcome of a key meeting held on May 30, 2023. In that meeting, the Centre decided to constitute four expert subcommittees, comprising specialists in pathology, biochemistry, haematology and microbiology from Central Government Hospitals, to define Standard Operating Procedures (SoPs) for sample collection, set up collection centres and formulate a policy for transport and storage of Covid-19 the court acknowledged that a Contempt Petition may not stand given that such a decision had been taken, it expressed concern over the apparent lack of follow-up. "Even though on first blush, the Contempt Petition may not vacuum, if any, of steps taken post the meeting of 30th May 2023, is a serious issue," the court said. Observing that there are "wide reports of Covid-19 being active in the community," the court underscored the urgency of formalising protocols and submitting a clear status update. "Though the Court is sanguine that steps would have been taken and protocols would have been in place, it is imperative for the respondent to place the same on record," it court directed Central Government Standing Counsel (CGSC) Monika Arora to personally ensure that the concerned officers are apprised of the order and that a detailed status report is filed within six weeks. The matter will next be heard on July 18, of 8:00 am on Monday, India had 3,961 active Covid-19 cases and 28 deaths, according to data from the Ministry of Health and Family Welfare. In the national capital Delhi, the active cases stood at Watch
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
US FDA approves Moderna's new lower-dose Covid-19 vaccine 'mNexspike'
It's made in a way that allows for a lower dose a fifth of the dose of its current Covid-19 vaccine, Spikevax by refining its immune target AP Washington The US approved a new Covid-19 vaccine made by Moderna late Friday but with limits on who can use it not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose a fifth of the dose of its current Covid-19 vaccine, Spikevax by refining its immune target. The approval adds an important new tool to help protect people at high risk of severe disease from Covid-19, Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another Covid-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the US has handled Covid-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective and more by some measures than the original shot, the company said. The news came just days after the Trump administration cancelled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
